한글목차

헌팅턴 병 치료 시장 규모는 예측 기간 동안 9.0%의 복합 연간 성장률(CAGR)로 성장하여 2031년까지 8억 510만 달러에 달할 것으로 예상됩니다.

그러나 HD를 유발하는 HTT 유전자의 돌연변이는 독성 돌연변이 헌팅틴 단백질(mHTT)을 생성합니다. 이 유전자 변이는 신경 기능 장애를 일으키고 결국 신경 퇴행을 일으 킵니다. 또한, HD의 임상 증상은 증상의 발현과 진행 모두에서 개인간에 크게 다릅니다. 따라서 복잡한 질병 병태 생리학은 시장 성장을 방해합니다.

유행학은 록다운, 여행 제한 및 COVID - 19를 다루는 건강 관리 자원의 재배포로 인해 헌팅턴 병의 임상시험의 대부분을 중단하거나 연기했습니다. 또한, 유행에 의해 야기된 세계 공급망의 혼란은 HD 환자를 위한 의약품 및 의료 용품의 가용성에 영향을 미쳤습니다. 따라서 COVID - 19 팬데믹은 시장에 부정적인 영향을 미쳤습니다.

약제 유형별 전망입니다.

헌팅턴 병 치료 시장은 약물의 유형에 따라 승인 약물과 적응 외약으로 나뉩니다. 2023년 적응 외약 부문은 헌팅턴 병 치료 시장에서 15.3%의 수익 점유율을 획득했습니다. 적응 외약은 정신 증상(우울증, 불안 등), 자극성, 인지 장애 등 헌팅턴병의 특정 증상을 관리하는 데 잠재적인 이점을 제공할 수 있습니다. 건강 관리 제공업체는 환자의 삶의 질에 큰 영향을 미치는 이러한 어려운 증상을 완화하기 위해 적응 외 옵션을 고려할 수 있습니다.

유통 채널별 전망입니다.

유통 채널을 기반으로 헌팅턴 병 치료 시장은 병원 약국, 약국 및 소매 약국, 온라인 약국으로 분류됩니다. 2023년에는 약국 및 소매 약국 부문이 헌팅턴 병 치료 시장에서 32.7%의 수익 점유율을 획득했습니다. 소매 약국에서는 무도병(불수의운동), 정신증상(우울증, 불안 등), 인지장애 등의 치료제을 포함한 헌팅턴병과 관련된 증상을 관리하는데 사용되는 다양한 약을 재고하고 있습니다.

연령별 전망입니다.

연령별로 보면 헌팅턴병 치료 시장은 50세 미만과 50세 이상으로 나뉘어져 있습니다. 2023년에는 50세 이상의 부문이 헌팅턴 병 치료 시장의 수익 점유율의 43.3%를 차지했습니다. 헌팅턴 병은 노인들에게 미묘한 증상과 비정상적인 증상을 나타낼 수 있으며 진단 지연으로 이어질 수 있습니다. 인지도와 진단 능력이 향상됨에 따라 50세 이상의 사람들이 HD로 진단되고 증상을 해결하고 삶의 질을 최적화하기 위한 치료 및 관리 전략의 시작이 촉구될 수 있음 있습니다.

지역별 전망입니다.

지역별로 보면 헌팅턴병 치료 시장은 북미, 유럽, 아시아태평양, 라틴아메리카, 중동, 아프리카에 걸쳐 분석되고 있습니다. 북미는 2023년 헌팅턴 병 치료 시장에서 42%의 수익 점유율을 기록했습니다. 북미는 다른 지역보다 헌팅턴병의 유병률이 상대적으로 높습니다. 이 질병은 북미의에서 눈에 띄는 유럽의계 인구들 사이에서 더 일반적으로 진단됩니다. 또한이 지역은 생물 의학 조사 및 의약품 혁신의 세계적인 리더입니다.

목차

제1장 시장 범위와 조사 방법

• 시장의 정의
• 목적
• 시장 범위
• 세분화
• 조사 방법

제2장 시장 요람

• 주요 하이라이트

제3장 시장 개요

• 소개
  • 개요
    • 시장구성과 시나리오
• 시장에 영향을 미치는 주요 요인
  • 시장 성장 촉진요인
  • 시장 성장 억제요인
  • 시장 기회
  • 시장의 과제
• Porter's Five Forces 분석

제4장 헌팅턴병 치료 시장 : 약제 유형별

• 세계 승인 의약품 시장 : 지역별
• 세계 적응외 의약품 시장 : 지역별

제5장 헌팅턴병 치료 시장 : 유통 채널별

• 세계 병원 약국 시장 : 지역별
• 세계 약국 및 소매 약국 시장 : 지역별
• 세계 온라인 약국 시장 : 지역별

제6장 헌팅턴병 치료 시장 : 연령별

• 세계 50세 이하 시장 : 지역별
• 세계 50세 이상 시장 : 지역별

제7장 헌팅턴병 치료 시장 : 지역별

• 북미
  • 북미 시장 : 국가별
    • 미국
    • 캐나다
    • 멕시코
    • 기타 북미
• 유럽
  • 유럽 시장 : 국가별
    • 독일
    • 영국
    • 프랑스
    • 러시아
    • 스페인
    • 이탈리아
    • 기타 유럽
• 아시아태평양
  • 아시아태평양 시장 : 국가별
    • 중국
    • 일본
    • 인도
    • 한국
    • 싱가포르
    • 말레이시아
    • 기타 아시아태평양
• 라틴아메리카, 중동, 아프리카
  • 라틴아메리카, 중동, 아프리카 시장 : 국가별
    • 브라질
    • 아르헨티나
    • 아랍에미리트(UAE)
    • 사우디아라비아
    • 남아프리카
    • 나이지리아
    • 기타 라틴아메리카, 중동, 아프리카

제8장 기업 프로파일

• Dr Reddy's Laboratories Ltd.
• Takeda Pharmaceutical Company Limited
• Sun Pharmaceutical Industries Ltd
• Hikma Pharmaceuticals PLC
• Camber Pharmaceuticals, Inc(Hetero Labs Limited)
• Teva Pharmaceutical Industries Ltd
• Bausch Health Companies, Inc
• Neurocrine Biosciences Inc
• Pfizer, Inc
• F Hoffmann - La Roche Ltd.

제9장 헌팅턴병 치료 시장의 성공 필수 조건

영문목차

The Global Huntington's Disease Treatment Market size is expected to reach $805.1 million by 2031, rising at a market growth of 9.0% CAGR during the forecast period.

The Asia-Pacific region's nations are investing in expanding and modernizing its hospitals, clinics, and specialized treatment facilities. Better facilities and access to healthcare enable HD patients to receive sophisticated treatment choices, interdisciplinary care, and early diagnosis. Consequently, the Asia pacific region would acquire nearly 25% of the total market share by 2031. Genetic diversity within the Asia Pacific region provides unique opportunities for studying Huntington's Disease genetics, disease variants, and population-specific factors influencing disease progression.

Huntington's disease is caused by a mutation in the HTT gene, which produces an abnormal form of the huntingtin protein. Moreover, RNA interference (RNAi) and antisense oligonucleotides (ASOs) are biotechnological approaches that can reduce the expression of the mutant HTT gene. Moreover, RNA interference (RNAi) and antisense oligonucleotides (ASOs) are biotechnological approaches that can reduce the expression of the mutant HTT gene. Additionally, Healthcare expenditure encompasses funding allocated to biomedical research, including neurodegenerative diseases like Huntington's disease. Furthermore, investments in healthcare infrastructure, such as specialized clinics, research centers, and laboratory facilities, are essential for advancing HD research and treatment. Therefore, rising healthcare expenditures and investments are propelling the market's growth.

However, A poisonous mutant huntingtin protein (mHTT) results from an HTT gene mutation that causes HD. This genetic mutation leads to neuronal dysfunction and eventual neurodegeneration. Moreover, the clinical manifestations of HD vary widely among individuals, both in terms of symptom onset and progression. Thus, complex disease pathophysiology is hampering the growth of the market.

The pandemic led to the suspension or delay of many clinical trials for Huntington's Disease due to lockdowns, travel restrictions, and the reallocation of healthcare resources to address COVID-19. In addition, the global supply chain disruptions caused by the pandemic affected the availability of medications and medical supplies for HD patients. Thus, the COVID-19 pandemic had a negative impact on the market.

Drug Type Outlook

Based on drug type, the Huntington's disease treatment market is divided into approved drugs and offlabel drugs. In 2023, the offlable drugs segment acquired 15.3% revenue share in the Huntington's disease treatment market. Off-label drugs may offer potential benefits in managing specific symptoms of Huntington's Disease, such as psychiatric symptoms (e.g., depression, anxiety), irritability, and cognitive impairment. Healthcare providers may explore off-label options to alleviate these challenging symptoms that significantly impact patient quality of life.

Distribution Channel Outlook

On the basis of distribution channel, the Huntington's disease treatment market is segmented into hospital pharmacies, drug stores & retail pharmacies, and online pharmacies. In 2023, the drug stores & retail pharmacies segment attained 32.7% revenue share in the Huntington's disease treatment market. Retail pharmacies stock a variety of medications used to manage symptoms associated with Huntington's Disease, including medications for chorea (involuntary movements), psychiatric symptoms (e.g., depression, anxiety), and cognitive impairments.

Age Outlook

By age, the Huntington's disease treatment market is bifurcated into below 50 years and above 50 years. The above 50 segment held 43.3% revenue share in the Huntington's disease treatment market in 2023. Huntington's Disease can present with subtle or atypical symptoms in older adults, leading to delays in diagnosis. As awareness and diagnostic capabilities improve, more individuals above 50 years old may receive a diagnosis of HD, prompting the initiation of treatment and management strategies to address symptoms and optimize quality of life.

Regional Outlook

Region-wise, the Huntington's disease treatment market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America region witnessed 42% revenue share in the Huntington's disease treatment market in 2023. North America has a relatively higher Huntington's Disease prevalence than other regions. The disease is more commonly diagnosed among populations of European descent, which are prominent in North America. Also, the region is a global leader in biomedical research and pharmaceutical innovation.

List of Key Companies Profiled

• Bausch Health Companies, Inc.
• Teva Pharmaceutical Industries Ltd.
• Camber Pharmaceuticals, Inc. (Hetero Labs Limited)
• Hikma Pharmaceuticals PLC
• Takeda Pharmaceutical Company Limited
• Sun Pharmaceutical Industries Ltd.
• Dr. Reddy's Laboratories Ltd.
• Neurocrine Biosciences Inc.
• Pfizer, Inc.
• F. Hoffmann-La Roche Ltd.

Global Huntington's Disease Treatment Market Report Segmentation

By Drug Type

• Approved Drugs
  • Tetrabenazine
  • Deutetrabenazine
• Offlabel Drugs

By Distribution Channel

• Hospital Pharmacies
• Drug Store & Retail Pharmacies
• Online Pharmacies

By Age

• Below 50 years
• Above 50 years

By Geography

• North America
  • US
  • Canada
  • Mexico
  • Rest of North America
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
• LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Table of Contents

Chapter 1. Market Scope & Methodology

• 1.1 Market Definition
• 1.2 Objectives
• 1.3 Market Scope
• 1.4 Segmentation
  • 1.4.1 Global Huntington's Disease Treatment Market, by Drug Type
  • 1.4.2 Global Huntington's Disease Treatment Market, by Distribution Channel
  • 1.4.3 Global Huntington's Disease Treatment Market, by Age
  • 1.4.4 Global Huntington's Disease Treatment Market, by Geography
• 1.5 Methodology for the research

Chapter 2. Market at a Glance

• 2.1 Key Highlights

Chapter 3. Market Overview

• 3.1 Introduction
  • 3.1.1 Overview
    • 3.1.1.1 Market Composition and Scenario
• 3.2 Key Factors Impacting the Market
  • 3.2.1 Market Drivers
  • 3.2.2 Market Restraints
  • 3.2.3 Market Opportunities
  • 3.2.4 Market Challenges
• 3.3 Porter Five Forces Analysis

Chapter 4. Global Huntington's Disease Treatment Market by Drug Type

• 4.1 Global Approved Drugs Market by Region
• 4.2 Global Huntington's Disease Treatment Market by Approved Drugs Type
  • 4.2.1 Global Tetrabenazine Market by Region
  • 4.2.2 Global Deutetrabenazine Market by Region
• 4.3 Global Offlabel Drugs Market by Region

Chapter 5. Global Huntington's Disease Treatment Market by Distribution Channel

• 5.1 Global Hospital Pharmacies Market by Region
• 5.2 Global Drug Store & Retail Pharmacies Market by Region
• 5.3 Global Online Pharmacies Market by Region

Chapter 6. Global Huntington's Disease Treatment Market by Age

• 6.1 Global Below 50 years Market by Region
• 6.2 Global Above 50 years Market by Region

Chapter 7. Global Huntington's Disease Treatment Market by Region

• 7.1 North America Huntington's Disease Treatment Market
  • 7.1.1 North America Huntington's Disease Treatment Market by Drug Type
    • 7.1.1.1 North America Approved Drugs Market by Region
    • 7.1.1.2 North America Huntington's Disease Treatment Market by Approved Drugs Type
      • 7.1.1.2.1 North America Tetrabenazine Market by Country
      • 7.1.1.2.2 North America Deutetrabenazine Market by Country
    • 7.1.1.3 North America Offlabel Drugs Market by Region
  • 7.1.2 North America Huntington's Disease Treatment Market by Distribution Channel
    • 7.1.2.1 North America Hospital Pharmacies Market by Country
    • 7.1.2.2 North America Drug Store & Retail Pharmacies Market by Country
    • 7.1.2.3 North America Online Pharmacies Market by Country
  • 7.1.3 North America Huntington's Disease Treatment Market by Age
    • 7.1.3.1 North America Below 50 years Market by Country
    • 7.1.3.2 North America Above 50 years Market by Country
  • 7.1.4 North America Huntington's Disease Treatment Market by Country
    • 7.1.4.1 US Huntington's Disease Treatment Market
      • 7.1.4.1.1 US Huntington's Disease Treatment Market by Drug Type
        • 7.1.4.1.1.1 US Huntington's Disease Treatment Market by Approved Drugs Type
      • 7.1.4.1.2 US Huntington's Disease Treatment Market by Distribution Channel
      • 7.1.4.1.3 US Huntington's Disease Treatment Market by Age
    • 7.1.4.2 Canada Huntington's Disease Treatment Market
      • 7.1.4.2.1 Canada Huntington's Disease Treatment Market by Drug Type
        • 7.1.4.2.1.1 Canada Huntington's Disease Treatment Market by Approved Drugs Type
      • 7.1.4.2.2 Canada Huntington's Disease Treatment Market by Distribution Channel
      • 7.1.4.2.3 Canada Huntington's Disease Treatment Market by Age
    • 7.1.4.3 Mexico Huntington's Disease Treatment Market
      • 7.1.4.3.1 Mexico Huntington's Disease Treatment Market by Drug Type
        • 7.1.4.3.1.1 Mexico Huntington's Disease Treatment Market by Approved Drugs Type
      • 7.1.4.3.2 Mexico Huntington's Disease Treatment Market by Distribution Channel
      • 7.1.4.3.3 Mexico Huntington's Disease Treatment Market by Age
    • 7.1.4.4 Rest of North America Huntington's Disease Treatment Market
      • 7.1.4.4.1 Rest of North America Huntington's Disease Treatment Market by Drug Type
        • 7.1.4.4.1.1 Rest of North America Huntington's Disease Treatment Market by Approved Drugs Type
      • 7.1.4.4.2 Rest of North America Huntington's Disease Treatment Market by Distribution Channel
      • 7.1.4.4.3 Rest of North America Huntington's Disease Treatment Market by Age
• 7.2 Europe Huntington's Disease Treatment Market
  • 7.2.1 Europe Huntington's Disease Treatment Market by Drug Type
    • 7.2.1.1 Europe Approved Drugs Market by Country
    • 7.2.1.2 Europe Huntington's Disease Treatment Market by Approved Drugs Type
      • 7.2.1.2.1 Europe Tetrabenazine Market by Country
      • 7.2.1.2.2 Europe Deutetrabenazine Market by Country
    • 7.2.1.3 Europe Offlabel Drugs Market by Country
  • 7.2.2 Europe Huntington's Disease Treatment Market by Distribution Channel
    • 7.2.2.1 Europe Hospital Pharmacies Market by Country
    • 7.2.2.2 Europe Drug Store & Retail Pharmacies Market by Country
    • 7.2.2.3 Europe Online Pharmacies Market by Country
  • 7.2.3 Europe Huntington's Disease Treatment Market by Age
    • 7.2.3.1 Europe Below 50 years Market by Country
    • 7.2.3.2 Europe Above 50 years Market by Country
  • 7.2.4 Europe Huntington's Disease Treatment Market by Country
    • 7.2.4.1 Germany Huntington's Disease Treatment Market
      • 7.2.4.1.1 Germany Huntington's Disease Treatment Market by Drug Type
        • 7.2.4.1.1.1 Germany Huntington's Disease Treatment Market by Approved Drugs Type
      • 7.2.4.1.2 Germany Huntington's Disease Treatment Market by Distribution Channel
      • 7.2.4.1.3 Germany Huntington's Disease Treatment Market by Age
    • 7.2.4.2 UK Huntington's Disease Treatment Market
      • 7.2.4.2.1 UK Huntington's Disease Treatment Market by Drug Type
        • 7.2.4.2.1.1 UK Huntington's Disease Treatment Market by Approved Drugs Type
      • 7.2.4.2.2 UK Huntington's Disease Treatment Market by Distribution Channel
      • 7.2.4.2.3 UK Huntington's Disease Treatment Market by Age
    • 7.2.4.3 France Huntington's Disease Treatment Market
      • 7.2.4.3.1 France Huntington's Disease Treatment Market by Drug Type
        • 7.2.4.3.1.1 France Huntington's Disease Treatment Market by Approved Drugs Type
      • 7.2.4.3.2 France Huntington's Disease Treatment Market by Distribution Channel
      • 7.2.4.3.3 France Huntington's Disease Treatment Market by Age
    • 7.2.4.4 Russia Huntington's Disease Treatment Market
      • 7.2.4.4.1 Russia Huntington's Disease Treatment Market by Drug Type
        • 7.2.4.4.1.1 Russia Huntington's Disease Treatment Market by Approved Drugs Type
      • 7.2.4.4.2 Russia Huntington's Disease Treatment Market by Distribution Channel
      • 7.2.4.4.3 Russia Huntington's Disease Treatment Market by Age
    • 7.2.4.5 Spain Huntington's Disease Treatment Market
      • 7.2.4.5.1 Spain Huntington's Disease Treatment Market by Drug Type
        • 7.2.4.5.1.1 Spain Huntington's Disease Treatment Market by Approved Drugs Type
      • 7.2.4.5.2 Spain Huntington's Disease Treatment Market by Distribution Channel
      • 7.2.4.5.3 Spain Huntington's Disease Treatment Market by Age
    • 7.2.4.6 Italy Huntington's Disease Treatment Market
      • 7.2.4.6.1 Italy Huntington's Disease Treatment Market by Drug Type
        • 7.2.4.6.1.1 Italy Huntington's Disease Treatment Market by Approved Drugs Type
      • 7.2.4.6.2 Italy Huntington's Disease Treatment Market by Distribution Channel
      • 7.2.4.6.3 Italy Huntington's Disease Treatment Market by Age
    • 7.2.4.7 Rest of Europe Huntington's Disease Treatment Market
      • 7.2.4.7.1 Rest of Europe Huntington's Disease Treatment Market by Drug Type
        • 7.2.4.7.1.1 Rest of Europe Huntington's Disease Treatment Market by Approved Drugs Type
      • 7.2.4.7.2 Rest of Europe Huntington's Disease Treatment Market by Distribution Channel
      • 7.2.4.7.3 Rest of Europe Huntington's Disease Treatment Market by Age
• 7.3 Asia Pacific Huntington's Disease Treatment Market
  • 7.3.1 Asia Pacific Huntington's Disease Treatment Market by Drug Type
    • 7.3.1.1 Asia Pacific Approved Drugs Market by Country
    • 7.3.1.2 Asia Pacific Huntington's Disease Treatment Market by Approved Drugs Type
      • 7.3.1.2.1 Asia Pacific Tetrabenazine Market by Country
      • 7.3.1.2.2 Asia Pacific Deutetrabenazine Market by Country
    • 7.3.1.3 Asia Pacific Offlabel Drugs Market by Country
  • 7.3.2 Asia Pacific Huntington's Disease Treatment Market by Distribution Channel
    • 7.3.2.1 Asia Pacific Hospital Pharmacies Market by Country
    • 7.3.2.2 Asia Pacific Drug Store & Retail Pharmacies Market by Country
    • 7.3.2.3 Asia Pacific Online Pharmacies Market by Country
  • 7.3.3 Asia Pacific Huntington's Disease Treatment Market by Age
    • 7.3.3.1 Asia Pacific Below 50 years Market by Country
    • 7.3.3.2 Asia Pacific Above 50 years Market by Country
  • 7.3.4 Asia Pacific Huntington's Disease Treatment Market by Country
    • 7.3.4.1 China Huntington's Disease Treatment Market
      • 7.3.4.1.1 China Huntington's Disease Treatment Market by Drug Type
        • 7.3.4.1.1.1 China Huntington's Disease Treatment Market by Approved Drugs Type
      • 7.3.4.1.2 China Huntington's Disease Treatment Market by Distribution Channel
      • 7.3.4.1.3 China Huntington's Disease Treatment Market by Age
    • 7.3.4.2 Japan Huntington's Disease Treatment Market
      • 7.3.4.2.1 Japan Huntington's Disease Treatment Market by Drug Type
        • 7.3.4.2.1.1 Japan Huntington's Disease Treatment Market by Approved Drugs Type
      • 7.3.4.2.2 Japan Huntington's Disease Treatment Market by Distribution Channel
      • 7.3.4.2.3 Japan Huntington's Disease Treatment Market by Age
    • 7.3.4.3 India Huntington's Disease Treatment Market
      • 7.3.4.3.1 India Huntington's Disease Treatment Market by Drug Type
        • 7.3.4.3.1.1 India Huntington's Disease Treatment Market by Approved Drugs Type
      • 7.3.4.3.2 India Huntington's Disease Treatment Market by Distribution Channel
      • 7.3.4.3.3 India Huntington's Disease Treatment Market by Age
    • 7.3.4.4 South Korea Huntington's Disease Treatment Market
      • 7.3.4.4.1 South Korea Huntington's Disease Treatment Market by Drug Type
        • 7.3.4.4.1.1 South Korea Huntington's Disease Treatment Market by Approved Drugs Type
      • 7.3.4.4.2 South Korea Huntington's Disease Treatment Market by Distribution Channel
      • 7.3.4.4.3 South Korea Huntington's Disease Treatment Market by Age
    • 7.3.4.5 Singapore Huntington's Disease Treatment Market
      • 7.3.4.5.1 Singapore Huntington's Disease Treatment Market by Drug Type
        • 7.3.4.5.1.1 Singapore Huntington's Disease Treatment Market by Approved Drugs Type
      • 7.3.4.5.2 Singapore Huntington's Disease Treatment Market by Distribution Channel
      • 7.3.4.5.3 Singapore Huntington's Disease Treatment Market by Age
    • 7.3.4.6 Malaysia Huntington's Disease Treatment Market
      • 7.3.4.6.1 Malaysia Huntington's Disease Treatment Market by Drug Type
        • 7.3.4.6.1.1 Malaysia Huntington's Disease Treatment Market by Approved Drugs Type
      • 7.3.4.6.2 Malaysia Huntington's Disease Treatment Market by Distribution Channel
      • 7.3.4.6.3 Malaysia Huntington's Disease Treatment Market by Age
    • 7.3.4.7 Rest of Asia Pacific Huntington's Disease Treatment Market
      • 7.3.4.7.1 Rest of Asia Pacific Huntington's Disease Treatment Market by Drug Type
        • 7.3.4.7.1.1 Rest of Asia Pacific Huntington's Disease Treatment Market by Approved Drugs Type
      • 7.3.4.7.2 Rest of Asia Pacific Huntington's Disease Treatment Market by Distribution Channel
      • 7.3.4.7.3 Rest of Asia Pacific Huntington's Disease Treatment Market by Age
• 7.4 LAMEA Huntington's Disease Treatment Market
  • 7.4.1 LAMEA Huntington's Disease Treatment Market by Drug Type
    • 7.4.1.1 LAMEA Approved Drugs Market by Country
    • 7.4.1.2 LAMEA Huntington's Disease Treatment Market by Approved Drugs Type
      • 7.4.1.2.1 LAMEA Tetrabenazine Market by Country
      • 7.4.1.2.2 LAMEA Deutetrabenazine Market by Country
    • 7.4.1.3 LAMEA Offlabel Drugs Market by Country
  • 7.4.2 LAMEA Huntington's Disease Treatment Market by Distribution Channel
    • 7.4.2.1 LAMEA Hospital Pharmacies Market by Country
    • 7.4.2.2 LAMEA Drug Store & Retail Pharmacies Market by Country
    • 7.4.2.3 LAMEA Online Pharmacies Market by Country
  • 7.4.3 LAMEA Huntington's Disease Treatment Market by Age
    • 7.4.3.1 LAMEA Below 50 years Market by Country
    • 7.4.3.2 LAMEA Above 50 years Market by Country
  • 7.4.4 LAMEA Huntington's Disease Treatment Market by Country
    • 7.4.4.1 Brazil Huntington's Disease Treatment Market
      • 7.4.4.1.1 Brazil Huntington's Disease Treatment Market by Drug Type
        • 7.4.4.1.1.1 Brazil Huntington's Disease Treatment Market by Approved Drugs Type
      • 7.4.4.1.2 Brazil Huntington's Disease Treatment Market by Distribution Channel
      • 7.4.4.1.3 Brazil Huntington's Disease Treatment Market by Age
    • 7.4.4.2 Argentina Huntington's Disease Treatment Market
      • 7.4.4.2.1 Argentina Huntington's Disease Treatment Market by Drug Type
        • 7.4.4.2.1.1 Argentina Huntington's Disease Treatment Market by Approved Drugs Type
      • 7.4.4.2.2 Argentina Huntington's Disease Treatment Market by Distribution Channel
      • 7.4.4.2.3 Argentina Huntington's Disease Treatment Market by Age
    • 7.4.4.3 UAE Huntington's Disease Treatment Market
      • 7.4.4.3.1 UAE Huntington's Disease Treatment Market by Drug Type
        • 7.4.4.3.1.1 UAE Huntington's Disease Treatment Market by Approved Drugs Type
      • 7.4.4.3.2 UAE Huntington's Disease Treatment Market by Distribution Channel
      • 7.4.4.3.3 UAE Huntington's Disease Treatment Market by Age
    • 7.4.4.4 Saudi Arabia Huntington's Disease Treatment Market
      • 7.4.4.4.1 Saudi Arabia Huntington's Disease Treatment Market by Drug Type
        • 7.4.4.4.1.1 Saudi Arabia Huntington's Disease Treatment Market by Approved Drugs Type
      • 7.4.4.4.2 Saudi Arabia Huntington's Disease Treatment Market by Distribution Channel
      • 7.4.4.4.3 Saudi Arabia Huntington's Disease Treatment Market by Age
    • 7.4.4.5 South Africa Huntington's Disease Treatment Market
      • 7.4.4.5.1 South Africa Huntington's Disease Treatment Market by Drug Type
        • 7.4.4.5.1.1 South Africa Huntington's Disease Treatment Market by Approved Drugs Type
      • 7.4.4.5.2 South Africa Huntington's Disease Treatment Market by Distribution Channel
      • 7.4.4.5.3 South Africa Huntington's Disease Treatment Market by Age
    • 7.4.4.6 Nigeria Huntington's Disease Treatment Market
      • 7.4.4.6.1 Nigeria Huntington's Disease Treatment Market by Drug Type
        • 7.4.4.6.1.1 Nigeria Huntington's Disease Treatment Market by Approved Drugs Type
      • 7.4.4.6.2 Nigeria Huntington's Disease Treatment Market by Distribution Channel
      • 7.4.4.6.3 Nigeria Huntington's Disease Treatment Market by Age
    • 7.4.4.7 Rest of LAMEA Huntington's Disease Treatment Market
      • 7.4.4.7.1 Rest of LAMEA Huntington's Disease Treatment Market by Drug Type
        • 7.4.4.7.1.1 Rest of LAMEA Huntington's Disease Treatment Market by Approved Drugs Type
      • 7.4.4.7.2 Rest of LAMEA Huntington's Disease Treatment Market by Distribution Channel
      • 7.4.4.7.3 Rest of LAMEA Huntington's Disease Treatment Market by Age

Chapter 8. Company Profiles

• 8.1 Dr. Reddy's Laboratories Ltd.
  • 8.1.1 Company Overview
  • 8.1.2 Financial Analysis
  • 8.1.3 Segmental and Regional Analysis
  • 8.1.4 Research & Development Expense
  • 8.1.5 SWOT Analysis
• 8.2 Takeda Pharmaceutical Company Limited
  • 8.2.1 Company Overview
  • 8.2.2 Financial Analysis
  • 8.2.3 Regional Analysis
  • 8.2.4 Research & Development Expense
  • 8.2.5 SWOT Analysis
• 8.3 Sun Pharmaceutical Industries Ltd.
  • 8.3.1 Company Overview
  • 8.3.2 Financial Analysis
  • 8.3.3 Regional Analysis
  • 8.3.4 Research & Development Expenses
  • 8.3.5 SWOT Analysis
• 8.4 Hikma Pharmaceuticals PLC
  • 8.4.1 Company Overview
  • 8.4.2 Financial Analysis
  • 8.4.3 Segmental and Regional Analysis
  • 8.4.4 Research & Development Expenses
• 8.5 Camber Pharmaceuticals, Inc. (Hetero Labs Limited)
  • 8.5.1 Company Overview
• 8.6 Teva Pharmaceutical Industries Ltd.
  • 8.6.1 Company Overview
  • 8.6.2 Financial Analysis
  • 8.6.3 Regional Analysis
  • 8.6.4 Research & Development Expenses
  • 8.6.5 SWOT Analysis
• 8.7 Bausch Health Companies, Inc
  • 8.7.1 Company Overview
  • 8.7.2 Financial Analysis
  • 8.7.3 Segmental and Regional Analysis
  • 8.7.4 Research & Development Expense
  • 8.7.5 SWOT Analysis
• 8.8 Neurocrine Biosciences Inc.
  • 8.8.1 Company Overview
  • 8.8.2 Financial Analysis
  • 8.8.3 Research & Development Expenses
• 8.9 Pfizer, Inc.
  • 8.9.1 Company Overview
  • 8.9.2 Financial Analysis
  • 8.9.3 Regional & Segmental Analysis
  • 8.9.4 Research & Development Expense
  • 8.9.5 SWOT Analysis
• 8.10. F. Hoffmann-La Roche Ltd.
  • 8.10.1 Company Overview
  • 8.10.2 Financial Analysis
  • 8.10.3 Segmental and Regional Analysis
  • 8.10.4 Research & Development Expense
  • 8.10.5 SWOT Analysis

Chapter 9. Winning Imperatives of Huntington's Disease Treatment Market